1 Min Read
March 21 (Reuters) - Checkpoint Therapeutics Inc:
* CHECKPOINT THERAPEUTICS INITIATES DOSE EXPANSION PORTION OF PHASE 1 TRIAL OF ANTI-PD-L1 ANTIBODY CK-301 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.